Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 399

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 399
---
 to a 0.3% decrease in average pricing, which is quoted in U.S. dollars, driven by increased pricing pressures and competitive dynamics in the diagnostics market. In addition to these market -specificdynamics, macroeconomic factors exacerbated the decline. The transition of Argentina’s government from Alberto Fernández to Javier Milei in December 2023 brought significant economic reforms aimed at reducing inflation and stabilizing the economy. These reforms, however, gave rise to pricing volatility and reduced consumer purchasing power within the healthcare sector, further impacting demand for diagnostic products and services.

209 Revenues from the Rewell segment increased by $61,536, or 111.3%, from $55,275 in the year ended June 30, 2023, to $116,811 in the year ended June 30, 2024. This growth is explained as follows: • volume effect: 29.5% of the increase ($18,153) is due to a 32.84% growth in the number of kits sold, reflecting expanded commercialization efforts and improved sales strategies; and • price effect: 70.5% of the increase ($43,383) is due to a 78.49% rise in the average price per kit, which is quoted in U.S. dollars, driven by adjustments in pricing strategies and increased direct -to -consumersales. Overall, approximately 93.6% and 6.4% of total revenues were derived from the Heritas Diagnostics segment and the Rewell segment, respectively, in the year ended June 30, 2024, compared to 97.1% and 3.0%, respectively, in the year ended June 30, 2023. Cost of revenues Cost of revenues decreased by $45,705, or 2.4%, from $1,920,443 in the year ended June 30, 2023, to $1,882,235 in the year ended June 30, 2024. The reduction was mainly attributed to lower demand for diagnostic tests, leading to a proportional decrease in the utilization of reagents, sequencing consumables, and sample processing services. In addition to the reduced test volumes, several operational improvements contributed to lower reagent and consumable consumption: • operational efficiencies: sequencing workflow optimizations, including reducing machine runtime, led to a more efficient use of reagents and consumables; • improved sequencing efficiency: enhancements in sequencing protocols resulted in a reduced need for reagents per sample, optimizing their usage